Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Crystalys Therapeutics, with $205M in funding, launches to advance a new gout treatment in early human trials.

flag Crystalys Therapeutics has launched with $205 million in funding to advance clinical trials for a new gout treatment, targeting the root causes of the painful inflammatory condition caused by uric acid buildup. flag The investment will support early-stage human trials to assess the drug’s safety, tolerability, and effectiveness, aiming to address unmet needs in gout care. flag The company, based in Ashburn, Virginia, is a private biotech focused on innovative therapies for metabolic and inflammatory diseases.

7 Articles